A new nanodrug for treating metabolic diseases
A Novel Nanodrug for Metabolic Disease Treatment
This study is testing a new oral medication designed to help people with type 2 diabetes and reduce the risk of liver and colorectal cancers by improving gut health, and it has shown promising results in mice.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11171208 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nanodrug aimed at treating metabolic diseases such as type 2 diabetes and conditions that can lead to liver and colorectal cancers. The approach involves creating an orally delivered drug that targets gut dysbiosis, which is linked to metabolic dysfunction. By utilizing advanced drug synthesis techniques, the researchers aim to enhance the signaling pathways that are often disrupted in patients with these conditions. The effectiveness of this drug has been tested in mouse models, showing promising results in improving metabolic health.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from metabolic diseases such as type 2 diabetes or those at risk for liver and colorectal cancers.
Not a fit: Patients who do not have metabolic diseases or related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves metabolic health and reduces the risk of cancer in affected patients.
How similar studies have performed: Previous research has shown success in using similar approaches to target gut dysbiosis for metabolic disease treatment, indicating potential for this novel drug.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Wan, Yu-Jui Yvonne — University of California at Davis
- Study coordinator: Wan, Yu-Jui Yvonne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.